Sign in
TerminatedPhase 4

Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 4
People taking part
10 people enrolled
Started
22 Jun 2021
Ended
8 May 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Gadoxetate disodium
  • Gadobenate dimeglumine
Record updated
25 September 2026
Why it stopped
Low Accrual

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Colorectal cancer patients
  • Age 18-80 years
  • No prior treatment including surgery
  • Prior imaging with suspected liver metastasis

Who cannot take part

  • Previous reaction to gadolinium contrast agents
  • Non-MR safe implants or metallic foreign bodies
  • History of claustrophobia or movement disorders likely to impact image quality
  • eGFR < 30 ml/min/1.73 m2
  • Age < 18 years or > 80 years

Where in United States

  • University of Colorado HospitalAurora, United States

About the trial

What the trial wants to find out

If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.

The 2 groups in the trial

  • Gadoxetate disodium exam first, Gadobenate Dimeglumine exam secondExisting treatment, for comparison

    The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver magnetic resonance imaging (MRI) for known or suspected colorectal cancer (CRC) metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-20 days, but in opposite order, determined randomly.

    Treatment: Gadoxetate disodium and Gadobenate dimeglumine

  • Gadobenate Dimeglumine exam first, Gadoxetate disodium exam secondTreatment being tested

    The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRI for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-20 days, but in opposite order, determined randomly.

    Treatment: Gadoxetate disodium and Gadobenate dimeglumine

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Liver Magnetic Resonance (MR) With an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR With Gadoxetate Disodium for the Detection of Hepatic Metastases
Record updated
25 September 2026